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Aims. The frequency of functional gastrointestinal disorders (FGIDs) in the general population of Mexico is unknown. Methods.
To determine the prevalence of FGIDs, associated depression, and health care utilization, a population-based sampling strategy
was used to select 500 households in the State of Tlaxcala, in central Mexico. Household interviews were conducted by two trained
physicians using the Rome II Modular Questionnaire, a health-care and medication used questionnaire and the CES-D depression
scale. Results. The most common FGIDs were IBS: 16.0% (95% CI: 12.9–19.5); functional bloating: 10.8% (8.2–13.9); unspeciﬁed
functional bowel disorder: 10.6% (8.0–13.6); and functional constipation (FC): 7.4% (5.3–10.1). Uninvestigated heartburn was
common:19.6%(16.2–23.4).AllFGIDswereequallyprevalentamongbothgenders,exceptforIBS(P = 0.001),IBS-C(P<0.001),
IBS-A/M (P = 0.049), and FC (P = 0.039) which were more frequent in women. Subjects with FGIDs reported higher frequencies
of medical visits: 34.6 versus 16.8%; use of medications: 40.7 versus 21.6%; (both P<0.001); and reported depression: 26.7 versus
6.7%, (P<0.001). Conclusion. In this ﬁrst population-based study of FGIDs in Mexico, heartburn, IBS, functional distension, and
FC were common. Only IBS, IBS-C, IBS-A/M, and FC were more frequent in women. Finally, FGIDs in Mexico had an increased
burden of health care utilization and depression.
1.Introduction
Functional gastrointestinal disorders (FGIDs) are very com-
mon and their global impact is often underestimated [1, 2]
due to their limited associated mortality [3]. However, it
is well documented that FGIDs have a negative impact on
health-related quality of life (HRQOL) and have a burden of
illness because of the number of physician visits, diagnostic
tests, and secondary economic losses due to work absen-
teeism [4].
In Latin America, there are few studies that have esti-
mated the prevalence and burden of FGIDs and the majority
have been conducted in selected populations [5–7]. In
Mexico,forexample,onlyonestudytodatehasevaluatedthe
prevalence of all FGIDs using the Rome II Modular Ques-
tionnaire (RIIQ) but focused on a University population
from Mexico City [8]. This study found that irritable bowel
syndrome (FC) (35%), uninvestigated heartburn (35%),
functional abdominal bloating, (21%) and functional con-
stipation (FC) (19%) were frequent. Interestingly, uninvesti-
gated dyspepsia was less common (8.0%) [8]. Also, IBS with
diarrhea predominance (IBS-D) was less frequent compared
to IBS with constipation (IBS-C): 4.6 versus 14.7% and the
latter was four times more common in women than men
[8]. A second study in Mexico in patients with IBS nationally
cared for in private practice, conﬁrmed the lower prevalence
of IBS-D compared to IBS-C and although all IBS subtypes
showed a female predominance, the percentage of men2 Gastroenterology Research and Practice
among those with IBS-D was 1.7 to 2.4 higher than in the
other subtypes [9]. Recently, our group reported the analysis
of a RIIQ database, noting that the proportion of women
among those fulﬁlling criteria for IBS and uninvestigated
dyspepsia (67.8 y 85.4%, resp.,) was signiﬁcantly higher than
the proportion of women among the group not fulﬁlling
criteria for any FGID (55.9%) [10]. In addition, compared to
men with IBS, women reported more frequently symptoms
related to constipation and abdominal distension [10].
We conducted a population-based study of FGIDs in
Mexico, to our knowledge, the ﬁrst such investigation. Based
on our previous study among volunteers in Mexico [8], we
hypothesized that uninvestigated heartburn, IBS, FC and
uninvestigated dyspepsia would be the most common FGIDs
and that all of these disorders together with IBS-C would
be more common in women, while IBS-D would be more
common in men. In addition, we included assessments of
health care utilization and psychological burden.
2. Methods
From June 1st to October 31st, 2005, a population-based,
cross-sectional study was conducted in the State of Tlaxcala,
in central Mexico. In the 2000 population registry (census)
of the Instituto Nacional de Estad´ ıstica y Geograf´ ıa (INEGI)
[National Institute of Statistics and Geography], Tlaxcala
had 962,646 inhabitants distributed in 60 cities/villages
[11]. Anticipating an IBS prevalence ranging between 10 to
20% based on a systematic review of population-based stud-
ies in North America that did not include Mexico [12], con-
sideringa10%precisionoftheoutcomefactorwitha99.99%
conﬁdence interval and a design eﬀect of 1, a sample of
243 subjects was estimated. Therefore, we decided to survey
a sample double that size. A population-based sample
strategy was used to select 500 subjects representing approx-
imately 0.05% of the State’s population. The interviews were
conducted in 500 randomly selected households and the
number of subjects surveyed within each city/village was
proportional to the number of their population. Exclusion
criteria included pregnancy and major medical illness at
the moment of the survey and a history of gastrointestinal
surgery and/or signiﬁcant psychiatric disease. Per protocol,
if the ﬁrst adult appearing in the household could not be
interviewed due to exclusion criteria or recruitment failure,
the neighboring household was selected.
Household interviews were conducted by two trained
physicians. Demographic information included age, gender,
occupation, and marital status. The RIIQ was used to assess
abdominal symptoms and diagnose the FGIDs by the Rome
II criteria [13]. The RIIQ had been previously translated and
validatedinMexicoandallowedustodeterminethepresence
of all FGIDs [8]. We acknowledge that the RIIQ identiﬁes
uninvestigated heartburn including functional heartburn
and gastroesophageal reﬂux (GER) [14] .T h eR o m eI I
criteria require a medical evaluation with endoscopy and/or
esophageal pH monitoring, to conﬁrm cases with functional
heartburn which was beyond the scope of the current pro-
tocol [15]. This is also applicable for dyspepsia, requiring
Table 1: Demographic characteristics of the study population.
Item Study population 95% CI
Age: (mean ± SD) 39.8 ±16.3 38.7–41.2
Sex: n (%)
(i) Women 305 (61.0) 56.6–65.3
(ii) Men 195 (39.0) 34.7–43.4
Occupation: n (%)
(i) Homemaker 220 (44.0) 39.6–48.5
(ii) Employee 115 (23.0) 19.4–26.9
(iii) Self-employed 100 (20.0) 16.6–23.8
(iv) Student 30 (6.0) 4.1–8.5
(v) Manual labor 20 (4.0) 2.5–6.1
(vi) Other activities 15 (3.0) 1.7–4.9
Marital Status: n (%)
(i) Married 303 (60.6) 56.2–64.9
(ii) Single 111 (22.2) 18.6–26.1
(iii) Civil Union 43 (8.6) 6.3–11.4
(iv) Widower 24 (4.8) 3.1–7.1
(v) Separated/Divorced 19 (3.8) 2.3–5.9
upper endoscopy to rule out organic causes and diagnosed
functional dyspepsia [16]. Therefore, subjects fulﬁlling cri-
teria for heartburn or dyspepsia were designated herein
as uninvestigated heartburn and uninvestigated dyspepsia,
respectively.
General questions regarding medical visits and medi-
cation use were included (have you consulted a physician
for gastric, or intestinal problems? And, have you taken or
are you currently taking any medication for your gastric or
intestinal problems?). The Center for Epidemiological Stud-
ies Depression Scale (CES-D) [17] served as the instrument
of psychological assessment. The CES-D is a 20 questions
instrument commonly used to screen for symptoms of
depression in the general population and has been validated
in Mexico [18]. A total CES-D score from 0 to 14 is consid-
erednegativefordepression,from15to21isconsideredmild
to moderate depression, and a score higher than 22 is major
depression [18]. Per standard, for the purpose of the current
study, we used a threshold of ≥15 to identify subjects with
depression.
The frequency of FGIDs is expressed in percentages with
95% Conﬁdence Interval (95% CI). Categorical variables
were analyzed by Chi-square and Fisher’s exact test and con-
tinuous variables with the Students t test. A P value ≤ 0.05
was considered signiﬁcant.
The protocol was approved by the local Institutional
Review Board (IRB) for Health Research—2901—of the
Hospital General de Zona No. 1 of the Instituto Mexicano del
Seguro Social (IMSS) in the State of Tlaxcala.
3. Results
The demographic characteristics of the study population are
presented in Table 1. In the initial random sample of 500
households, 56 subjects were recruitment failures because ofGastroenterology Research and Practice 3
lack of availability or refusal and 10 because of inaccurate
census information. In addition, ﬁve subjects were excluded
due to medical reasons. In each case, a subject was selected
from a neighboring household, per protocol. In the study
population, two-thirds were women and almost a half were
homemakers.
Criteria for at least one FGID were fulﬁlled by 292
subjects (58.4%) while 208 (41.6%) were without a FGID
diagnosis herein designated as “controls”. The groups were
similar in terms of age (mean ± SD): 40.3 ± 16.1 versus
39.5 ± 16.5 (P = 0.568); however, there were more women
among those with FGIDs versus controls: 64.4% versus
56.2% (P = 0.039). Table 2 depicts the general frequency of
each FGID, including a summary by gender. The most
common diagnoses were uninvestigated heartburn followed
by IBS, functional abdominal bloating, unspeciﬁed func-
tional bowel disorder, and FC. Interestingly, dyspepsia was
relatively uncommon.
When comparing the group with FGIDs versus controls,
subjects with levator ani syndrome (mean ± SD: 54.6 ±
28.8 years old) and fecal incontinence (49.7 ± 19.3), were
signiﬁcantly (P<0.05) older than controls (40.4 ± 16.1).
The prevalence of the majority of the FGIDs was similar
between women and men except for IBS, IBS-C, IBS
Alternating/Mixed (IBS-A/M), and functional abdominal
bloating, which were signiﬁcantly more common among
women.
Importantly, the burden of health care utilization and
psychological disease was increased in those with FGIDs.
Subjects with FGIDs reported higher number of medical
visits: 35.0 versus 17.0% (P<0.05) and use of medication
for gastrointestinal symptoms: 41.0 versus 22.0% (P<0.05).
In addition, depression was more frequent in the group with
FGIDs compared to controls: 26.4% versus 6.7% (P<0.001)
Table 3. Further, depression was present in 37.6% of the
subjects with FGIDs that consulted for medical care versus
20.4% that did not consult (P<0.01).
4. Discussion
To the best of our knowledge this is the ﬁrst population-
based study to estimate the prevalence of the FGIDs in Mex-
ico using the Rome II criteria. The FGIDs were common in
the general population as nearly sixty percent fulﬁlled
criteria for at least one FGID. The most common diagnoses
were uninvestigated heartburn, IBS, functional abdominal
bloating, unspeciﬁed functional bowel disorders, and FC. As
postulated, IBS, IBS-C, and IBS-A/M were all signiﬁcantly
more frequent in women than men and there was a trend
for FC. Notwithstanding, functional abdominal bloating was
alsomorecommoninwomen.Finally,comparedtocontrols,
subjectswithFGIDsweretwofoldmorelikelytoseekmedical
consultationsandtousemedicationsforGIsymptoms,while
depression was four times more likely.
4.1. Uninvestigated Heartburn. In our population, one-ﬁfth
of the subjects fulﬁlled criteria for heartburn. This ﬁnding
is in agreement with those from other population-based
studies that have reported a high frequency of GER-related
symptoms. For example in Spain, in a telephone-based
survey, Diaz-Rubio et al. found that 32% of the subjects
reported GER symptoms [19]. In our study the diagnosis of
heartburn was based only on symptom reporting with the
RIIQ without additional diagnostic investigation, therefore
the true prevalence of functional heartburn cannot be esti-
mated. In a previous study in Mexico in patients fulﬁlling
criteria for heartburn according to the RIIQ, 62.0% had GER
conﬁrmed by endoscopy and/or pH monitoring [20]; this
study was limited by the fact that pH impedance testing was
not used. Notwithstanding, based on those results, we may
assume that of the 98 subjects that fulﬁlled criteria for
heartburninthepresentstudy,61(62.0%)willprobablyhave
true GER and 37 (38.0%) may have functional heartburn,
thus estimating a prevalence of 7.4% (37/500) for functional
heartburn in our population. This result is in agreement
with a population-based study from Australia using Rome
II criteria, reporting a prevalence of functional heartburn of
10.4% [21].
4.2. Uninvestigated Dyspepsia. The low frequency (7.0%) of
dyspepsia is an interesting ﬁnding, which may reﬂect a true
low-populationprevalenceoffunctionaldyspepsiainMexico
and/or it may be related with aspects of the RIIQ in the
assessmentoffunctionaldyspepsia. Similartouninvestigated
heartburn, subjects did not undergo endoscopy to rule out
organic etiologies. Thus, we suggest that the prevalence
reported herein corresponds to uninvestigated dyspepsia.
This result is in accordance with our previous study among
volunteers in Mexico City with the RIIQ, where dyspepsia
was present in 8.0% of the subjects [8]. Furthermore, a
similar study from Canada with the RIIQ found a very low
prevalence of dyspepsia (1.8%) [22]. This contrasts with
a study from Brazil that used modiﬁed Rome II criteria
and found a 48% frequency of uninvestigated dyspepsia
[23]. These observations suggest that in Mexico, dyspepsia is
uncommon compared to other FGIDs such as IBS, under-
standing that the Rome II criteria may have inherent limita-
tions with respect to the diagnosis of functional dyspepsia.
4.3.IrritableBowelSyndrome. Globally,IBSisconsideredthe
most frequent FGID with a prevalence that ranges from 5
to 25% [1, 22]. This variability is probably related to the
use of diﬀerent diagnostic criteria between the studies,
study designed diﬀerences (e.g., convenience samples versus
population-based sampling), as well as true population
diﬀerences. In fact, a recent joint conference of the Rome
Foundation and the World Gastroenterology Organization
(WGO) about the global perspective of IBS concluded that it
was necessary to conduct population-based studies to esti-
mate the frequency of this functional bowel disorder world-
wide[24]. The16.0% frequencyof IBSin thecurrentstudy is
concordant with a parallel study that was conducted in
Central America (Nicaragua) using Rome II criteria that
reported a 13.2% prevalence [25] and with the 19.9%
reported in a population-based study from South America
(Colombia), using Rome III criteria [26]. In contrast, our4 Gastroenterology Research and Practice
Table 2: Prevalence of functional gastrointestinal disorders.
FGID All (n = 500) Women (n = 305) Men (n = 195) P (women versus men)
n % (95% CI) n (%) n (%)
292 58.4 (53.9–62.8) 188 (61.6) 104 (53.5) 0.066
Esophageal disorders
Globus 9 1.8 (0.8–3.4) 6 (2.0) 3 (1.5) 0.725
Rumination syndrome 4 0.8 (0.2–2.0) 2 (0.7) 2 (1.0) 0.651
Functional chest pain of
presumed esophageal origin 15 3.0 (1.7–4.9) 11 (3.6) 4 (2.1) 0.320
Uninvestigated heartburn 98 19.6 (16.2–23.4) 57 (18.7) 41 (21.0) 0.521
Dysphagia 9 1.8 (0.8–3.4) 5 (1.6) 4 (2.1) 0.735
Gastroduodenal disorders
Uninvestigated dyspepsia 35 7.0 (4.9–9.6) 23 (7.5) 12 (6.2) 0.553
(i) Ulcer-like 17 3.4 (2.0–5.4) 12 (3.9) 5 (2.6) 0.410
(ii) Dysmotility-like 18 3.6 (2.1–5.6) 11 (3.6) 7 (3.6) 0.992
Aerophagia 28 5.6 (3.8–8.0) 15 (4.9) 13 (6.7) 0.399
Functional vomiting 10 2.0 (1.0–3.6) 8 (2.6) 2 (1.0) 0.213
Bowel disorders
IBS 80 16.0 (12.9–19.5) 62 (20.3) 18 (9.2) 0.001
(i) IBS-D 12 2.4 (1.2–4.2) 7 (2.3) 5 (2.6) 0.841
(ii) IBS-C 33 6.6 (4.6–9.1) 29 (9.5) 4 (2.1) 0.001
(iii) IBS-A/M 45 7.0 (4.9–9.6) 26 (8.5) 9 (4.6) 0.003
Functional abdominal bloating 54 10.8 (8.2–13.9) 41 (13.4) 13 (6.7) 0.017
Functional constipation 37 7.4 (5.3–10.1) 28 (9.2) 9 (4.6) 0.057
Functional diarrhea 7 1.4 (0.6–2.9) 3 (1.0) 4 (2.1) 0.322
Unspeciﬁed eunctional bowel
disorder 53 10.6 (8.0–13.6) 30 (9.8) 23 (11.8) 0.488
Functional abdominal pain
Functional abdominal pain
syndrome 5 1.0 (0.3–2.3) 4 (1.3) 1 (0.5) 0.381
Unspeciﬁed functional
abdominal pain 8 1.6 (0.7–3.1) 6 (2.0) 2 (1.0) 0.413
Biliary disorders
Gallbladder dysfunction 6 1.2 (0.4–2.6) 5 (1.6) 1 (0.5) 0.259
Sphincter of oddi dysfunction 1 0.2 (0-1.1) 1 (0.3) 0 (0.0) 0.423
Anorectal disorders
Functional fecal incontinence 23 4.6 (2.9–6.8) 13 (4.3) 10 (5.1) 0.652
(i) Soiling 14 2.8 (1.5–4.7) 7 (2.3) 7 (3.6) 0.392
(ii) Gross incontinence 9 1.8 (0.8–3.4) 6 (2.0) 3 (1.5) 0.725
Levator ani syndrome 7 1.4 (0.6–2.9) 3 (1.0) 4 (2.1) 0.322
Proctalgia fugax 31 6.2 (4.3–8.7) 22 (7.2) 9 (4.6) 0.240
Dyssynergia 10 2.0 (1.0–3.6) 8 (2.6) 2 (1.0) 0.213
IBS: irritable bowel syndrome, IBS-D: irritable bowel syndrome diarrhea predominant, IBS-C: irritable bowel syndrome constipation predominant, IBS-A/M:
irritable bowel syndrome alternating/mixed. There were no diﬀerences in the prevalence of the diﬀerent FGIDs between women versus men, except for IBS
IBS-C IBS-A/M and functional abdominal bloating that were all more frequent among women and a trend for functional constipation.
prevalence is eight times higher than the one reported in a
multinational study in Europe using Rome II criteria [1]. In
that study, dyspepsia was also more common than IBS, with
a prevalence that ranged from 15.1% to 23.9% [27, 28]. In
the current study, IBS proved to be more frequent in women
thanmenandintheIBSsubtypes,IBS-C,andIBS-A/M.This
gender diﬀerence did not hold up for IBS-D as has been re-
ported in other studies [29]. Further, in this population-
based study IBS-A/M is the most frequent subtype followed
by IBS-C and IBS-D. This is consistent with our prior studies
in Mexico [8, 9]. The higher frequency of IBS-C compared
to IBS-D seems to be a common ﬁnding in Latin AmericanGastroenterology Research and Practice 5
Table 3: Depression, medical visits, and use of medications by FGID.
Diagnosis Age Women Depression
(CES-D)
Medical visits for
GI problems
Use of medications
for GI problems
n (mean ± SD) (%) (%) (%) (%)
Esophageal disorders
Globus 9 40.4 ± 12.0 66.7 11.1 11.1 44.4
Rumination syndrome 4 46.0 ± 11.2 50.0 75.0 50.0 50.0
Functional chest pain of
presumed esophageal origin 15 39.4 ± 14.9 73.3 46.7 33.3 60.0
Uninvestigated heartburn 98 37.2 ± 13.8 58.2 26.5 45.9 44.9
Dysphagia 9 50.3 ± 17.9 55.5 44.4 55.6 55.6
Gastroduodenal disorders
Uninvestigated dyspepsia 35 37.6 ± 14.7 65.7 17.1 25.7 40.0
(i) Ulcer-like 17 40.1 ± 18.3 70.6 17.6 23.5 41.2
(ii) Dysmotility-like 18 35.2 ± 10.4 61.1 16.7 27.8 38.9
Aerophagia 28 41.7 ± 19.7 53.6 50.0 39.3 53.6
Functional vomiting 10 32.2 ± 12.7 80.0 30.0 70.0 80.0
Bowel disorders
IBS 80 40.4 ± 17.5 77.5 47.5 56.2 67.5
(i) IBS-D 12 43.3 ± 20.8 58.3 50.0 50.0 66.7
(ii) IBS-C 33 40.7 ± 20.1 87.9 60.6 66.7 69.7
(iii) IBS-A/M 45 39.3 ± 13.6 74.3 40.0 48.6 65.7
Functional abdominal bloating 54 37.0 ± 16.2 75.9 24.1 40.7 42.6
Functional constipation 37 37.6 ± 18.7 75.7 24.3 35.1 37.8
Functional diarrhea 7 42.3 ± 24.2 42.9 42.9 42.9 28.6
Unspeciﬁed functional bowel
disorder 53 38.5 ± 15.9 56.6 13.2 17.0 26.4
Functional abdominal pain
Functional abdominal pain
syndrome 5 38.2 ± 9.6 80.0 100.0 60.0 60.0
Unspeciﬁed functional
abdominal pain 8 35.4 ± 8.7 75.0 25.0 75.0 50.0
Biliary disorders
Gallbladder dysfunction 6 27.7 ± 8.8 83.3 50.0 66.7 83.3
Sphincter of oddi dysfunction 1 27.0 100.0 0 0 0
Anorectal disorders
Functional fecal incontinence 23 49.6 ± 19.2 56.5 52.2 65.2 60.9
(i) Soiling 14 45.4 ± 15.9 50.0 50.0 71.4 57.1
(ii) Gross incontinence 9 56.2 ± 23.0 66.7 55.6 55.6 66.7
Levator ani syndrome 7 54.6 ± 28.8 42.9 71.4 71.4 71.4
Proctalgia fugax 31 41.4 ± 16.5 71.0 61.3 45.2 54.8
Dyssynergia 10 42.3 ± 19.9 80.0 60.0 30.0 40.0
CES-D: center for epidemiological studies depression scale, GI: gastrointestinal, IBS: irritable bowel syndrome, IBS-D: irritable bowel syndrome diarrhea
predominant, IBS-C: irritable bowel syndrome constipation predominant, IBS-A/M: irritable bowel syndrome alternating/mixed.
studies [26, 30], except for Argentina [31] where IBS-D is the
predominant subtype. This latter discordance might relate to
genetic and environmental inﬂuences in populations such as
Argentina with a greater European inﬂuence. Also, in one
of the ﬁrst cross-cultural studies of IBS conducted in the
USA, Mexico, Canada, England, Italy, Israel, India, and
China, using the Bowel Symptom Scale (BSS), diarrhea was
less frequent than constipation [32]. The Mexican subjects
reported the highest score for constipation while those from
China reported the highest score for diarrhea [32]. The
higher frequency of IBS-D in China was conﬁrmed in a
recent study among patients with IBS using the Rome II
criteria,inwhich65.9%wasdiagnosedasIBS-Dwhile26.4%
was diagnosed as IBS-C [33]. The contrasts between the6 Gastroenterology Research and Practice
diﬀerent studies underscore the importance of diagnostic
criteria, study methodology, and subject populations, all im-
portant factors than can inﬂuence the reported frequencies
of IBS and the IBS subtypes. Use of standard criteria and
methodology is imperative in future studies to elucidate the
worldwide frequency of IBS.
4.4. Functional Constipation. A recent systematic review and
meta-analysis of population-based studies from around the
world, with limited data from Latin America, reported a
pooled prevalence of 14% (95% CI: 12–17) for FC. The
prevalenceofFCwaslowerinSouthEastAsianstudiesandin
those using the Rome II or III criteria [34]. The lower
prevalence found in our study using the Rome II criteria
[7.4% (5.3–10.1)] is concordant. In contrast, a recent meta-
analysis that included the results from the current survey
and those from other available studies in Mexico reported
a pooled prevalence of FC of 14.4% (12.6–16.6). Although
this meta-analysis found similar ﬁgures to those from the
ﬁrst systematic review [35], they are higher than the ones
fromthecurrentsurvey,probablyinﬂuencedbytheinclusion
of data from studies conducted in convenience samples in
Mexicocontrarytothecurrentoneusingapopulation-based
sampling strategy.
4.5. The Burden of FGIDs: Health Care Utilization and De-
pression. Psychological comorbidities such as anxiety and
depression have been associated with FGIDs. For example,
depressionhasbeenassociatedwithGERsymptoms [36,37];
patients with IBS and functional dyspepsia [38]; IBS-C with
higher symptoms severity [39, 40]; IBS with lower HRQOL
[39, 40]. Although psychological comorbidities are frequent
among FGID subjects that seek medical care, few studies
have analyzed such associations in subjects with FGIDs from
the community [41]. Furthermore, subjects with depression
in the community report more frequently gastrointestinal
symptoms such as abdominal pain, diarrhea, constipation,
dyspepsia, and/or IBS [42]. In the current study, we used
a validated instrument to screen for depression, and we
conﬁrmed that depression is four times more likely to be
present among subjects with FGIDs than those without a
FGIDandinthosethatconsultedcomparedtothosewhodid
not. This ﬁnding is in agreement with a study in primary
care showing that severe depression was ﬁve times more
likely among subjects with gastrointestinal symptoms [43].
With regard to IBS, we found that 47.5% of our subjects
reported depression. This is consistent with a previous study
among patients that consulted a referral center in Mexico, in
which 46.0% had trait depression according to the Hospital
Anxiety and Depression Scale (HAD) [44]. In summary,
these results suggest that depression in subjects with FGIDs
in the community is common and is more frequent among
those that seek medical care.
The high frequency of FGIDs in the general population is
remarkable and suggests that having at least one FGID is
“normal”.Thisﬁndingisinagreementwithdatafromastudy
that followed subjects for over 20 years in Olmsted County
Minnesota and reported that 89% fulﬁlled criteria for at least
one FGID [45]. Also, in this population-based cohort, health
care utilization was increased in FGIDs and IBS subjects.
One-third of the subjects with FGIDs had related medical
care, thus they can be considered “patients”. Among those
with IBS, 56.2% had recent medical visits for GI symptoms,
thereby also considered “patients”. Our results are similar to
those from other parts of the world [46]. In addition, almost
70% of the IBS subjects had used medications for their
symptoms. These ﬁndings provide an indirect estimation of
the IBS burden of illness in Mexico.
Our study has several limitations. It was conducted in
a single State in Mexico; however, we consider that it is re-
presentative of the mestizo population which predominates
in this country [47]. Secondly, we did not include an as-
sessment of socioeconomic status or its possible relation to
the FGIDs, nor to the consultation behavior. Third, while we
did not screen for anxiety, we used a validated depression
instrument, thereby strengthening our results. Lastly, the
survey was conducted using the Rome II and not the more
recent Rome III criteria. However, a Rome III-based epi-
demiological study is underway in Mexico and Central
America and these results will allow us to further elucidate
the FGIDs prevalence and potential instrument diﬀerences
[48].
In conclusion, in this population-based study in Mexico,
FGIDs and IBS are observed to be common with important
gender diﬀerences for IBS and functional abdominal bloat-
ing. Among subjects with FGIDs and/or IBS, health care
utilization is increased and a positive association with de-
pression is observed. Further, studies of FGIDs epidemiology
in Mexico and Latin America are warranted.
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